Skip to content

Effects of Microcrystalline Titanium Dioxide With Covalently Linked Monovalent Silver Ions on Complications After Total Hysterectomy ( ISTIAB-0)

Trial on the Use of Microcrystalline Titanium Dioxide With Covalently Linked Monovalent Silver Ions (TIAB) in the Formulation of Vaginal Capsules in the Prevention of Complications After Total Hysterectomy

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03791294
Acronym
ISTIAB-0
Enrollment
200
Registered
2019-01-02
Start date
2019-01-01
Completion date
2019-12-31
Last updated
2019-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding, Complication, Postoperative, Infection

Brief summary

Total hysterectomy is one of the most performed surgical procedures in the world and it is associated with post-operative complications. The postoperative morbidity rate is estimated to vary from 3% to 8% with a readmission rate of 5-7%. The most frequent postoperative complications are urinary tract infections, wound infection of the vaginal vault, vault cellulitis, bleeding, suture dehiscence, pelvic abscess. The introduction of routine antibiotic prophylaxis has significantly reduced the risk of infectious complications, which however remains higher than other clean surgery, mainly due to contamination by the vaginal bacterial flora. In this scenario, the introduction of adjuvant factors acting on bacterial flora, can contribute to reduce the risk of post-surgical complications. The cationic silver ions (Ag +) stabilized by covalent link with Titanium dioxide (TiO2), the TIAB, maximizes the properties of silver by optimizing the antibiotic action and disruptive properties of the pathogenic biofilm of bacteria and fungi. Thanks to these properties, TIAB is able to enhance the antibiotic action by reducing the risk of antibiotic resistance and recurrent infections linked to the biofilm. Re-establishing the optimal vaginal microenvironment represents a fundamental step reducing the risk of infections in the surgical site, since the vagina is a non-sterile environment populated by bacterial species that can generate biofilm and potentially infect the site of surgery. In addition to microbicidal and disruptive biofilm activity, TIAB has demonstrated a direct action on tissue regeneration processes by stimulating the production of collagen and its modeling. Different clinical trials have reported a cicatrizing and re-epithelializing action of TIAB administered vaginally in the context of cervical conization for pathology related to HPV. Without showing any notable adverse effects or a negative action on lactobacillary flora with an overall good therapy tolerance by patients. On the basis of the available evidence, the investigators conduct a randomized controlled clinical trial to determine if TIAB treatment in the formulation of vaginal capsules TIAGIN (TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract) is able to reduce the incidence of infectious complications, that are related to altered healing of post-hysterectomy vaginal suture.

Interventions

TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract

Sponsors

Università degli Studi dell'Insubria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women underwent laparoscopic total hysterectomy for benign gynecological pathology

Exclusion criteria

* Women underwent non-laparoscopic total hysterectomy * Women underwent laparoscopic total hysterectomy for malignant pathology * Patients with diabetes mellitus in insulin therapy * Smoking patients * Patients suffering from chronic rheumatic diseases or chronic diseases not in adequate control.

Design outcomes

Primary

MeasureTime frameDescription
Vaginal bleedingAt the 30th post operative dayat least one episode of red vaginal blood loss
Vaginal vault infectionAt the 30th post operative dayat least one episode of inflammation and infection in the vaginal vault suture requiring antibiotic therapy
Urinary tract infectionAt the 30th post operative dayat least one episode of signs and symptoms requiring empiric antibiotic therapy
Dehiscence of vaginal vault sutureAt the 30th post operative dayDehiscence of vaginal vault suture requiring repeat surgery
ReadmissionAt the 30th post operative dayAt least one episode of readmission related to postoperative complications

Secondary

MeasureTime frameDescription
Adverse eventsAt the 30th post operative dayAdverse events due to the use of vaginal capsule therapy: erythema, vaginal and vulvar pruritus, dermatitis.

Contacts

Primary ContactSimone Garzon, M.D.
sgarzon@studenti.uninsubria.it+39 347 0782287
Backup ContactAntonio Simone Laganà, M.D.
antoniosimone.lagana@asst-settelaghi.it+39 329 6279579

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026